Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease
Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease
Sharanya Ford, Bettina Wick-Urban, Remo Panaccione, Kendall Beck et al.
Citations
1 citations
Journal
Journal of Crohn s and Colitis
Topics
Inflammatory Bowel Disease
Field-Weighted Citation Impact (FWCI)
1.82
article
Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease
Sharanya Ford, Bettina Wick-Urban, Remo Panaccione, Kendall Beck, Javier P. Gisbert, Severine A.R.A. Vermeire, Valencia P. Remple, Elena Dubcenco, Laurent Peyrin‐Biroulet, Silvio Danese, María Chaparro, Edward V. Loftus, Benjamin Duncan, Justin Klaff, Grace Naling, Yibo Wang, Namita Joshi, Jean–Frédéric Colombel, Smitha Suravaram
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Crohn s and ColitisVol. 20(1)
Institutions
Mayo Clinic (US), University of Calgary (CA), University of California, San Francisco (US), Ludwigshafen University of Business and Society (DE), McGill University Health Centre (CA), AbbVie (United States) (US), Mayo Clinic in Arizona (US), AbbVie (Germany) (DE), Klinikum Ludwigshafen (DE), Hospital Universitario de La Princesa (ES), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), IRCCS Ospedale San Raffaele (IT), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), Universidad Autónoma de Madrid (ES), Université de Lorraine (FR), Icahn School of Medicine at Mount Sinai (US), KU Leuven (BE)